← Leaderboards
Jorge C Blanco
Virion Systems, Inc.
$16,547,347
Attributed
$20,367,492
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,367,492 · 13
By mechanism
R01$11,267,512 · 3
R44$4,306,284 · 2
R42$1,867,924 · 1
R41$1,293,694 · 2
R21$944,854 · 2
R43$538,794 · 2
Top collaborators
- Stefanie N. Vogel16 shared
Most similar at Virion Systems, Inc.
Same institution · by research overlap
- Gregory A. Prince$2,090,385
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseResponseCotton RatsPathogenInfectionVirusInflammatoryAnimalsProductionMolecularMediatingLungVaccinesBaseSignal TransductionPublishingGene ExpressionSigmodonCytokineFamilyAnimal ModelSignal PathwayRespiratory Syncytial VirusCells
Grant awards (43)
RXR/PPARg heterodimer agonists for treating virus-induced acute lung injury$72,930
R03 · FY2025 · AI · contact PI
Inducible HMGB1 antagonist for viral-induced acute lung injury.$488,080
R41 · FY2024 · HL · contact PI
RXR/PPARg heterodimer agonists for treating virus-induced acute lung injury$75,500
R03 · FY2024 · AI · contact PI
Inducible HMGB1 antagonist for viral-induced acute lung injury.$62,894
R41 · FY2024 · HL · contact PI
Inducible HMGB1 antagonist for viral-induced acute lung injury.$29,640
R41 · FY2024 · HL · contact PI
Inducible HMGB1 antagonist for viral-induced acute lung injury.$488,080
R41 · FY2023 · HL · contact PI
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)$190,063
R21 · FY2022 · AI
Development of VLP vaccine for RSV$1,000,000
R44 · FY2021 · AI · contact PI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$544,376
R01 · FY2021 · AI
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)$241,700
R21 · FY2021 · AI
Development of VLP vaccine for RSV$1,000,000
R44 · FY2020 · AI · contact PI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$533,933
R01 · FY2020 · AI
Development of VLP vaccine for RSV$476,975
R44 · FY2020 · AI · contact PI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$52,216
R01 · FY2020 · AI
Development of VLP vaccine for RSV$1,000,000
R44 · FY2019 · AI · contact PI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$533,933
R01 · FY2019 · AI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$533,933
R01 · FY2018 · AI
Development of VLP vaccine for RSV$933,962
R42 · FY2017 · AI · contact PI
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury$547,143
R01 · FY2017 · AI
Development of VLP vaccine for RSV$933,962
R42 · FY2016 · AI · contact PI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza$865,457
R01 · FY2016 · AI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza$865,457
R01 · FY2015 · AI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza$878,832
R01 · FY2014 · AI
Development of VPL Vaccine for RSV$225,000
R41 · FY2014 · AI · contact PI
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza$784,554
R01 · FY2013 · AI
The role of TLR4 and RSV F protein in immunity to RSV$495,638
R01 · FY2013 · AI · contact PI
Development of the Cotton Rat Model of Rhinovirus Infection and Disease$238,284
R21 · FY2013 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$524,620
R01 · FY2012 · AI · contact PI
Development of the Cotton Rat Model of Rhinovirus Infection and Disease$274,807
R21 · FY2012 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$532,693
R01 · FY2011 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$414,971
R01 · FY2010 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$131,953
R01 · FY2010 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$128,948
R01 · FY2010 · AI · contact PI
The role of TLR4 and RSV F protein in immunity to RSV$474,338
R01 · FY2009 · AI · contact PI
The Role of TLR4 and RSV F Protein in Immunity to RSV$495,850
R01 · FY2008 · AI · contact PI
Establishment fo HIV infection in cotton rats$424,749
R44 · FY2008 · AI · contact PI
The Role of TLR4 and RSV F Protein in Immunity to RSV$490,735
R01 · FY2007 · AI · contact PI
Establishment fo HIV infection in cotton rats$404,560
R44 · FY2007 · AI · contact PI
The Role of TLR4 and RSV F Protein in Immunity to RSV$490,668
R01 · FY2006 · AI · contact PI
Treatment of RSV Bronchiolitis with NSAIDs$438,794
R43 · FY2006 · AI · contact PI
The Role of TLR4 and RSV F Protein in Immunity to RSV$473,632
R01 · FY2005 · AI
The Role of TLR4 and RSV F Protein in Immunity to RSV$473,632
R01 · FY2004 · AI
Establishment of HIV Infection in cotton rats$100,000
R43 · FY2003 · AI